Company Description
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload.
It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.
Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V.
for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000.
Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Country | United States |
| Founded | 1994 |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,310 |
| CEO | Dr. Michael M. Morrissey Ph.D. |
Contact Details
Address: 1851 Harbor Bay Parkway Alameda, California 94502 United States | |
| Phone | (650) 837-7000 |
| Website | exelixis.com |
Stock Details
| Ticker Symbol | EXEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000939767 |
| CUSIP Number | 30161Q104 |
| ISIN Number | US30161Q1040 |
| Employer ID | 04-3257395 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder and Chair of the Board |
| Dr. Michael M. Morrissey Ph.D. | Chief Executive Officer, President and Director |
| Christopher J. Senner | Executive Vice President and Chief Financial Officer |
| Jeffrey J. Hessekiel J.D. | Executive Vice President, General Counsel and Secretary |
| Patrick J. Haley M.B.A. | Executive Vice President of Commercial |
| Dr. Dana T. Aftab Ph.D. | Executive Vice President of Discovery and Translational Research and Chief Scientific Officer |
| Susan T. Hubbard | Executive Vice President of Public Affairs and Investor Relations |
| Laura Dillard | Executive Vice President of Human Resources |
| Dr. Peter Lamb Ph.D. | Executive Vice President of Scientific Strategy |
| Dr. Anne Champsaur M.D. | Senior Vice President of Drug Safety |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 144 | Filing |
| Feb 23, 2024 | 144 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 10-K | Annual Report |
| Feb 6, 2024 | 8-K | Current Report |